F&P Healthcare investors murmur not shout over pay incentive bump
ANALYSIS: In other countries, shareholder dissent over executive bonuses is rising. Here, FPH boss Lewis Gradon got a 5% pay incentive bump with barely a whisper.
WATCH: NBR senior journalist Fiona Rotherham speaks with Simon Shepherd.
What’s at stake: Fisher & Paykel Healthcare shareholders approved 5% pay incentive bump for CEO and managing director Lewis Gradon without murmur.
The background: Elsewhere, as evidenced at the Xero annual shareholder meeting the same day, shareholder dissent with executive remuneration is rising. That's largely because the gap continues to widen between what the top executives and workers get paid.
The players: Fisher & Paykel Healthcare, Xero , NZ Shareholders’ Association, Ryman Healthcare, Lewis Gradon.
It was a polite and orderly affair as we’ve come to expect from Fisher & Paykel Healthcare (FPH) annual shareholder meetings.
Shareholders barely made a murmur when asked to approve tweaks that will deliver a 5% bump in the discretionary long-term variable remuneration (DLTVR) issued to Lewis
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Key points
What’s at stake: Fisher & Paykel Healthcare shareholders approved 5% pay incentive bump for CEO and managing director Lewis Gradon without murmur.
The background: Elsewhere, as evidenced at the Xero annual shareholder meeting the same day, shareholder dissent with executive remuneration is rising. That's largely because the gap continues to widen between what the top executives and workers get paid.
The players: Fisher & Paykel Healthcare, Xero , NZ Shareholders’ Association, Ryman Healthcare, Lewis Gradon.
